MVM invested $20 million in Optinose. Optinose markets XHANCE, an innovative drug delivery system that delivers steroids high and deep into the nasal cavity for the treatment of certain types of chronic sinusitis. XHANCE is also being evaluated in phase III clinical studies as a treatment for all forms of chronic sinusitis. If successful, XHANCE would be the first drug therapy approved by the FDA for the treatment of all forms of chronic sinusitis, a condition that affects over eight million US patients.
Most chronic sinusitis patients are initially prescribed over-the-counter intranasal steroid sprays which are typically inadequate because they don’t reach the sinuses, which are located deep in the nasal cavity. Patients are then left with poor treatment options, including: systemic steroids, invasive surgery, or very expensive biologic drugs.
XHANCE provides patients with a new, effective alternative which avoids the complications and limitations of these other treatments. Adoption of XHANCE has been robust with annual revenue approaching $70 million and demonstrated strong revenue growth throughout 2021.
Optinose is based in Yardely, Pennsylvania. The company plans to appoint Drs. Eric Bednarski and Kyle Dempsey to the board.
MVM invests in Nalu Medical
February 17, 2022
CARLSBAD, Calif. (PRWEB) February 17, 2022 Nalu Medical, Inc. (“Nalu”), a private company focused on innovative and minimally invasive solutions for […]
Clarivate acquires Patient Connect
December 22, 2021
Clarivate Plc (NYSE:CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced that […]
MVM invests in Vero Biotech
December 15, 2021
VERO Biotech Inc., a fast-growing commercial business dedicated to improving the lives of patients through innovative technologies, today announced the […]
Paragon 28, Inc. Announces Pricing of Initial Public Offering
October 15, 2021
ENGLEWOOD, Colo., Oct. 15, 2021 /PRNewswire/ — Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and […]
MVM invests in InBrace
September 8, 2021
MVM invested $15 million in InBrace. InBrace is an orthodontic company that created the novel SmartwireTM, a new category in […]
Valneva Announces Positive Phase 3 Pivotal Results for its Single-Shot Chikungunya Vaccine Candidate
August 6, 2021
Saint Herblain (France), August 5, 2021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company focused on the […]
Vertos mild® Patients Demonstrate Durable 5 Year Outcomes
May 18, 2021
Most Minimally Invasive Lumbar Decompression (mild®) providers are very familiar with the 1-year study conducted by Nagy Mekhail, MD, PhD […]
Valneva Announces the Pricing of its Initial Public Offering on Nasdaq
May 11, 2021
Saint-Herblain (France), May 6, 2021 – Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for […]
eXmoor pharma secures £12m ($17m) from healthcare investment firm MVM marking milestone towards significant expansion plans
March 16, 2021
eXmoor, the expert cell and gene therapy (CGT) services company (Bristol, England), has announced an initial investment of £12m ($17m) […]